Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

NCT00142974 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
120
Enrollment
INDUSTRY
Sponsor class

Stopped This study was terminated early in April 2005 due to low patient enrollment

Conditions

Interventions

Sponsor

Novartis